WANT TO LEARN MORE?

Takeda Host Kristi Christensen: Thank you, Troyce. First, I wanted to say hello! Good evening! Thank you for joining us tonight and thank you to the HAEA (Hereditary Angioedema Association) for hosting tonight's webinar and I appreciate all that information Troyce and I have the pleasure of introducing you to our two speakers tonight. If you do not already know these two, I am thrilled that I get to be the one to introduce you.

Dr. Daniel Soteres is out of Colorado Springs, Colorado. He is in private practice there and he will be our physician and immunologist speaker this evening.

Pam is joining us as our patient ambassador speaker, and she has been a speaker with us for six years. As we get started, just as a housekeeping reminder, even though Troyce did mention it, we are going to hold any questions that come in over Q&A until the close of the program. If we do not address your specific question, the HAEA follows up after the program in the next day or two to answer those questions for you. At this point I am thrilled to turn it over to Dr. Soteres. Thank you so much for doing this tonight.

HCP Speaker Dr. Soteres:Hey, thanks y'all and it is a pleasure to be a part of this. It is great to have all of you all online with us.

TAKHZYRO is what we are discussing tonight. You are going to join 3250+ people who have chosen to prevent HAE (HEREDITARY ANGIOEDEMA) attacks before they happen.

That is all since 2018. So, what is TAKHZYRO? It is a prescription medicine used to prevent attacks of HAE in people two years of age and older. You heard that right. Two years of age and older. More on that later.

It's not known if TAKHZYRO is safe in those under two years of age.

There are, of course, safety slides throughout this presentation. Here is your introduction to that: TAKHZYRO may cause serious side effects like allergic reactions. Some of those symptoms might be wheezing, breathing difficulty, chest tightness, increased heart rate, faintness, rash, or hives.

I am Dr. Soteres. I'm a board-certified allergy immunologist in Colorado Springs. We have a Clinical Research Center here. I am a clinical professor on faculty with the University of Colorado Health Sciences Center. I have been a primary investigator for studies in a range of topics, specifically in HAE.

I've been doing clinical research trials. I date this by my son's age, he's 18. I have been doing this for about 17 years.

Here is my guiding principle: I try to consider the whole patient while treating all their health concerns. I should include that I am a speaker for Takada tonight. I have been a consultant with them, and I do get payment for this presentation, just to be clear.

These slides are not for reproduction and are limited to the scope of our presentation tonight. So, what we're going to cover today is HAE, what is it, the impact of HAE attacks, and how to work with your doctor to create a personalized HAE management plan.

You are also going to hear about TAKHZYRO from a real patient's experience. That's where Pam comes in. You're going to learn about a treatment option to help prevent HAE attacks in those two years and older.

Great. Next, we will go to Pam.

Patient Ambassador Pam: Hello everyone, I want to thank you for joining us for this webinar. My name is Pam and I have been a patient speaker for Takada since 2017 and I am so thankful that you have spent your valuable time tonight to join us for this webinar.

My story will be broken up into two parts, the first being about my experience living with HAE, and the second part will be about my life today, and my experiences managing my HAE with Takeda’s preventive medication, TAKHZYRO. You'll also see pictures of my life. The highs, the lows, and the people who matter the most to me. I promise to do my very best to explain who these people are, and what these photos mean. So, with that, let us get started.

This is going to be a little different; I'm not going to start at the beginning when my HAE presented itself. Rather, I want you to know and feel what my life has been like living with this condition. Now, of course I'm showing you this wedding picture because that was long before I knew that I had HAE, probably another decade before I actually was diagnosed. It was a long struggle to get to that point as I know it was for many of you.

I'm going to focus on two parts of my life, my career as a journalist, and my life raising my kids as a single parent. I am going to start with my career.

It was the late 80s and into the 90s where I enjoyed a career as a reporter before taking increasingly higher roles within the news department. I worked both in front of the camera as an on-air reporter and anchor, and behind as a news director.

Everywhere I looked and everything I saw and induced stress; stress from deadlines, stress from stories, wherever I went, it was just with me.

But you grow accustomed to it. It's like the drum beat of your life and you adapt. But no matter how comfortable I was within that environment, I also found myself battling HAE attacks due to the stress. I did not know what they were at the time, but too many times I found myself sitting in my car after a long day dealing with an attack, or the aftereffects of attacks.

The worst part about that period in time, was that my attacks were often abdominal. It was like a screwdriver being driven into my abdomen.

Staying upright and not wincing in pain was all I could do to get through the day, whether I was in the newsroom or out on assignment. Whenever these attacks happen, my focus would change. Just get through it and get to the weekend. Then I could rest.

I did everything in my power to overcome the challenges HAE presented me before and even after I was diagnosed in the early 1990s. I would be reporting on location from whatever story I'd be covering and hoping an abdominal attack would ease its grip on me between takes.

I'd use all my vacation time to cover the days I missed dealing with my attacks so nobody would question my dedication to the job. It was all I could do to protect my career. It was a career I loved from the invasiveness of this disease.

But in doing so, I also found myself struggling through obligations at home with my children.

I was a single mother, a widow to three young girls. My husband, who you see in these pictures with our daughters, in fact, the one in front of the fireplace, was taken, not very long before he passed away. So, the girls were still young.

After he died, I was alone grasping the life as a single parent with a demanding career and children who needed me.

HAE is persistent and completely unpredictable. It does not choose the right time or the right place. Usually, it's always the wrong time in the wrong place, and as much as I felt that at work, I felt it even more at home.

I didn't miss many important events, but there were some. One was an elementary open house. My daughter had been working on her project for weeks. I wasn't going to make it because of an abdominal attack.

She walked in the room, stood beside my bed, and burst into tears, saying, why can't you just go?

The guilt and helplessness I felt were a lot worse than the attack itself.

But I just couldn't bring myself to get out of bed. All I wanted to do was be there for her, but my attack, like the ones I've described already, just wouldn't let go.

It was like wave after wave of pain seized my stomach and I felt like I couldn't move, let alone be there for her. There was this feeling of shame, like I was letting everyone down around me. Shockingly, this wasn't the turning point in my journey with HAE.

That came when my oldest daughter was diagnosed with HAE. I really started learning about the disease, what to do for it, what the future held, and how to make it better for the next generation. All the aspects of living with HAE that I had ignored for so many years; the types of H AE attacks people experience that triggers management plan options, all of it became something I researched, discussed, and followed.

My first step was to reach out to the HAE community, which is how I found the US hereditary angioedema association, or as we know the, HAEA.

I have to tell you that my first HAEA meeting was amazing. I didn't have to explain what I had. We started talking about coping, what worked for others and how to improve life. I also realized that it was time to seriously consider treatment options. I wanted to set a good example for my children, and I needed to connect with a doctor who could help me manage my HAE. More importantly, I needed to have something that would allow me to live a life less impacted and controlled by my HAE attacks. I show you this picture from my wedding because after I was diagnosed, and started putting the pieces together, I did figure out where this had come from. My dad on the far side of the picture is who I had gotten HAE from, and then my grandmother is who he had gotten it from. Then of course, I passed it on to my two children. That is about as far as I could go back in the family to figure out where that family line had come with HAE.

So going back to the story, I decided to get my first HAE treatment and at that time it was an on-demand medication, which I had used for many, many years. This treatment was a lifeline for the life I was living. I finally had something to combat the attacks, particularly the abdominal attacks that were stopping me from being fully present in my kids' lives, my life, and work.

This was my first experience with any semblance of control with my HAE attacks and it felt great.

I had finally taken a step toward living with my HAE, rather than always enduring painful attack after painful attack.

But as the years went on, I saw myself battling the aftereffects of an attack despite using my acute treatment. Because using your on-demand medication means you are still having an HAE attack.

This after effect, the same effect I mentioned earlier that stole weekends and nights and moments from my family, pushed me toward prevention. What if I could treat the swells before they ever came? Thanks for listening to this first part of my story. I'll hand it back to Dr. Soteres before coming back to tell you a little more about my decision to take TAKHZYRO and how I'm doing today.

HCP Speaker Dr. Soteres: That’s a great story, Pam. Thank you for sharing that. I have so many thoughts. I can't wait till the question session to ask you my questions about some of the story.

We're going to move forward talking about the disease state. This is about hereditary angioedema tonight. It is a rare genetic condition affecting about one in 50,000 people.

What does that mean? I always try to put these numbers in perspective. Well, in the US, we have a population of about 300 million and for one in 50,000, we are talking about 6000 or 7000 people in the United States who have hereditary angioedema. Another way to put that in perspective is anybody ever found a four-leaf clover? Well, that is about one in 10,000.

HAE attacks are the result of an imbalance in blood proteins starting with C1 inhibitor, and this affects other chemicals like kallikrein and bradykinin.

Bob here, you see him pictured as a real patient with HAE and we see the impact from a facial attack of hereditary angioedema. Of course, HAE attacks can start in one location and spread to another. They can include areas like the face, the throat, abdomen, genitalia, hands, and feet.

HAE is unpredictable. I think Pam really outlined that quite well. It can change over time and your next attack may be nothing like your last attack. So unpredictable, debilitating, and potentially life threatening, those throat attacks can be quite a concern.

Past attacks do not predict future attacks, or whether the airway may become affected. Disease severity can change over time, so it's important to make a management plan with your doctor and review it regularly.

You're going to review your HAE management plan at each visit. I'm a doctor, I work in clinical practice, and I see close to 1500 patients a year. I love it when my patients come with a list of questions. I can tell you from personal experience. I'm a doctor and so is my wife. When my kids were young, and it was my turn to take him to the doctor's office, my wife would tell me all the questions I was supposed to ask. I would get there and forget them, and maybe remember some of them. Then I'd get home and she would say, 'what about this, this, and this?' I am like 'oh, I forgot to ask that one!'

Anyway, I think it is great to use this as an avenue to write down some of these and take these answers to your providers. If you want to make a difference on the impact that HAE has on your life, here are some topics to discuss with your doctor. On the left-hand side, you see topics to discuss at the first visit, the average number of attacks you experience per month, including the severity and location, whether you have missed work, school, or other activities due to an HAE attack and how often, the awareness of treatments and whether you've researched any, and how on demand and preventative therapies work. At your follow-up visits every visit thereafter; Again, average number of attacks per month including severity and location, how often you feel the need to use your on-demand treatment, how the unpredictability of HAE is affecting you, and how preventative treatment may impact the frequency and or severity of those attacks.

The 2020 US HAEA guidelines recommend a personalized approach to HAE management. Patients should focus on two general areas of treatment. One is on-demand treatment, the other is long-term preventative treatment. In the on-demand category, we're thinking patients should have access to at least two doses of their on-demand therapy, and every attack should be considered for treatment. Long-term preventative therapy should be considered for every patient based on their individual needs. You're going to review your HAE management plan regularly with your doctor and discuss if you should be considered for long-term preventative treatment.

Stop and think; what are some of the ways that HAE has impacted your life in the past 6 to 12 months? Here are some thoughts; for starters, the unpredictability of attacks - I will give you an example. I love to mountain bike; it is a thing I do for fun. One of my HAE patients likes to mountain bike also. I was talking with her one afternoon, just following up on the phone with how she was doing. She said, 'oh, I had to miss a mountain bike trip with my friends because I had an HAE attack' and I said, 'hold on a second, I thought you said you weren't having a lot of attacks?' She's like, 'well, you know, I didn't really count that one.' We ended up in a whole conversation about how maybe the disease is affecting more of your day-to-day and week-to-week decisions, work life, recreation than you originally thought. So many people are used to just managing it saying, 'I'll just deal with it this time.' But the bigger picture might be a little more than the person next to you is having to manage.

How often have you had attacks, and what is the severity of your attacks, and have you had any hospital visits? That of course is an important data point.

The 2020 US HAEA guidelines recommend TAKHZYRO as one of the first line therapies for long-term prevention. I should say that at your presentation and certainly available online and many sources, you can get the prescribing information for TAKHZYRO. This includes the full list of indications and safety as well.

So, we have a poll question. What is most important to you when considering a preventative treatment?

We have chosen one. We're going to talk about these. Oh, wow., 88% are in favor of long-term attack reduction. 13% were concerned about the safety profile. The other options: dosing schedule, how the treatment is administered, and patient support services, those were zero. The main one long-term attack prevention and then in second place safety profile. Thank you.

Indications and important safety information. TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema in people two years of age and older. It is not known if it's safe and effective in patients younger than two years of age.

It may cause serious side effects; we have already reviewed these at the very beginning. This is the list of allergic reaction concerns, wheezing, breathing difficulties, chest tightness, increased heart rate, faintness, rash, and hives.

Remember, the most common side effects seen with TAKHZYRO have really been injection site reactions, which would be pain, redness and bruising at the site of the location, upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. We see a list of contact numbers here and if there are concerns about side effects, you would want to be talking with your prescribing. healthcare provider, and you can also report those to the FDA at this 1-800 number.

Additionally, TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you're pregnant or planning to become pregnant, or you are breastfeeding or planning to breastfeed.

There is a broad range of people with HAE. TAKHZYRO is the number one prescribed HAE preventative treatment. People who've experienced TAKHZYRO include children, adolescents, and adults with HAE, people with mild moderate or severe hereditary angioedema, and more than 3250 people have been prescribed TAKHZYRO since 2018.

The warnings on here we have already reviewed, so that is great. We can move forward.

TAKHZYRO offers adolescents and adults proven HAE attack reduction, the possibility of 0 attacks for up to a year, and one subcutaneous self-injection every two weeks.

In a 6 1/2-month clinical trial of 125 people with HAE 12 and older, TAKHZYRO reduced the number of monthly attacks compared to placebo.

People taking TAKHZYRO also had fewer moderate or severe attacks, and less attacks requiring acute treatment compared with the placebo group as well.

They extended the study for 2 1/2 years. That is an open label, so no more placebo control. This was 212 people 12 and older with HAE. Some of those people had zero attacks for up to a year as well.

Imagine a life with fewer HAE attacks. The first study is what led to the FDA approval of TAKHZYRO. That was the 6 1/2-month clinical research trial with 125 people 12 and older. The main goal of the study was the ability of TAKHZYRO to reduce the frequency of HAE attacks. On average, people taking TAKHZYRO 300 mg every two weeks had much fewer attacks and less severity of their attacks. 44% of the people had zero attacks.

More details from this 6 1/2-month study, people had an average of 83% fewer moderate or severe attacks compared to the placebo group, and 87% had fewer attacks requiring on-demand treatment compared with placebo.

The second study was completed after FDA approval. This is the 2 1/2-year open label extension study with 212 people, each of them 12 years or older with HAE.

The main goal of this study was to evaluate the long-term safety of TAKHZYRO, 300 mg every two weeks. These people knew they were receiving TAKHZYRO, and of course that can influence the study results. On average, 87% of people had fewer attacks compared with their baseline number of attacks, and 69% of people had zero attacks for up to a year.

So, freedom from daily dosing with TAKHZYRO. It takes less than one minute to self-inject and it is dosed every two weeks.

There are three choices for injection site. The middle column is 2 weeks between each dose, and on the right are 3 choices for injection site. So, the slide, if you can imagine, reads 123, less than one minute to self-inject, 2 weeks between each dose and three choices for injection site.

We have reviewed the warnings at the bottom here so we can move forward to the next slide.

This is an important point, reaching steady state for people 12 years of age and older. What do we mean by steady state? With the first dose of TAKHZYRO, the medicine will start to build up in the body and over the first six doses, TAKHZYRO will reach a constant level, also known as steady state.

We see those in in the graphic there on the bottom, the doses are numbered 1 2 3 4 5 6 and seven. We see that around 2 1/2 months. That's the two-week dosing dose 6. That's when we're at steady state in the body.

TAKHZYRO safety results have been established in one of the largest prevention studies in HAE.

While it may cause serious side effects, including allergic reactions, you're going to contact your healthcare providers or get emergency help for that situation. Injection sites were really the most common side effect of TAKHZYRO. If we look at the safety information and the graphic on the right, we look across the top and we see column one; the most common side effects in the study, and then in the middle column we see TAKHZYRO in red there, and the placebo column. We look at injection site reactions for the first row and we see 52% for TAKHZYRO, and about 34% for the placebo. We can follow that graphic down and we see the upper respiratory infections that are very similar to placebo at 29% and 32%, headache at 21 and 22%, rash 7 and 5%. Then we see dizziness at 6% and zero. We see diarrhea and muscle aches as well.

In the 2 1/2-year Open label extension trial, remember this one was specifically focused on the safety data, the most common side effects seen in the long-term open label study were injection site reactions, upper respiratory infection, and headache.

We see the side effects listed in the left-hand column, and TAKHZYRO 300 mg every two weeks in the right-hand column: Injection site pain, upper respiratory infections, headaches. Then we see some joint pain, back pain, diarrhea, sinus concerns, influenza, nausea, and urinary tract infections. When my patients have concerns about the side effects of medications, I really look at it as an opportunity to have a discussion. It doesn't mean that the drug isn't right for you or it's not working. It might just be a barrier to overcome. For me, I love it when they come in with a list of questions. If these are on your mind, you should be writing these down and discussing them with your healthcare provider who prescribes this to further your conversation and knowledge.

TAKHZYRO was studied in children. Safety was the main goal of the study. The study included 21 children with HAE two to less than 12 years of age and taking 1 subcutaneous injection every two or four weeks. The safety profile was evaluated in a 52-week open label. That means no placebo in the study of 21 children with HAE from 2 to less than 12 years old.

The recommended dosage is 150 mg every two weeks for children from 6 to 12 years old and the dosage is every four weeks for those two to six years old.

The ability of TAKHZYRO to prevent HAE attacks in children was measured as a secondary objective of the study.

So, safety was established in the largest pediatric trial of any preventative treatment in HAE. In the 52-week study, there were no serious side effects reported, no discontinuations due to the side effects, and no allergic reactions related to TAKHZYRO.

Overall, the safety and tolerability of TAKHZYRO were similar between the adult and the pediatric patients. The most common side effects seen in the 12-month open label Pediatric study were again, the injection site reactions with pain and redness listed. We have a very similar graphic on the right-hand side here. We see the most common related TEAEs treatment and emergent adverse event. Then we see the TAKHZYRO with the dosing 2- or 4-weeks injection site pain, redness, swelling at administration, site pain, and site reactions.

The effectiveness of TAKHZYRO in children was a secondary goal of the 52-week study, and that was to measure the ability of TAKHZYRO to prevent HAE attacks in children two to less than 12 years old.

The efficacy data from the 6 1/2-month study in people 12 and older and data from the 52-week study showed similar levels of TAKHZYRO were reached in the body for adults and children. This was another main goal of the 52-week trial.

There are a few things to note about this study when considering efficacy. The study was not designed to understand how well TAKHZYRO works in children. The 21 children included knew they were taking TAKHZYRO. Again, there was no placebo. For comparison, these details make it difficult to determine how well TAKHZYRO decreased HAE attacks in children.

On average, children had 95% fewer HAE attacks compared to before starting the study. 76% of children were attack free for the entire 52-week study.

Dosing that fits in your child's life when it comes to your child's HAE treatment; it helps if the dosing schedule works with their lifestyle. Self-administration is not recommended for those two to less than 12 years old and the recommended dosages again for children two to less than six are 150 mg every four weeks for children 6 to less than 12, 150 mg every two weeks. If your child is taking TAKHZYRO every two weeks and it's well controlled, meaning they have zero HAE attacks for more than six months, their doctor may consider switching them to every four-week dosing.

Ada shares her daughter's experience with TAKHZYRO. Isn't she cute? I like Kenzleigh here. I'm just going to read through this, and I'm not going to change my voice at all, so forgive me. There's a lot on the page, but we will just walk through this together and you all can enjoy Kenzleigh’s cute photos. What made you decide to start Kenzleigh on TAKHZYRO? 'Well, my doctor told me that Kenzleigh might be eligible to take part in a TAKHZYRO study for children.

I was familiar with TAKHZYRO because my sister takes it, and it works for her. I knew right away I wanted to start her on it, especially after seeing the clinical studies. Kenzleigh was having face and throat swells. It was clear that her on demand treatment was not enough. We are so grateful that the TAKHZYRO study came along at the right time for her.

How has Kenzleigh responded to TAKHZYRO? So far TAKHZYRO has helped manage Kenzleigh 's HAE attacks. We know we can rely on TAKHZYRO, and my hope is that she can continue to take it for as long as she needs.

What advice do you have for patients of children with HAE? Do not give up. Your child needs to be strong. Work with your doctor to find the solution that works best for your child. Be brave, be present and be knowledgeable about disease and medicine.'

Start to imagine your TAKHZYRO experience. HAE attacks can be unpredictable, debilitating and potentially life threatening.

In a 6 1/2-month clinical study for people 12 years of age and older, taking TAKHZYRO 300 mg every two weeks, people experienced 87% fewer attacks on average compared with placebo.

Freedom from daily dosing; once every two weeks for people six years of age and older, or every four weeks for people two to less than six years of age. Remember, more than 3250 people in the US have been prescribed TAKHZYRO since 2008.

All right, we are back to Pam.

Patient Ambassador Pam: Thanks Dr. Soteres

Dr. Soteres is talking about TAKHZYRO, but in my story, we were back where I was just starting to take the on-demand medication, and that would really have gotten me in the fight. I was finally able to experience some relief from my HAE attacks. But like I said, what comes after an attack was still there. So as time went on, the novelty of treating with an on-demand medication only kind of wore off and I started to see all the ways my HAE attacks were still impacting my life.

I kept wondering, could we do more?

It was not a single attack that made the idea of prevention interesting to me. It was years of attack after attack after attack that made me realize the importance of what if.

What if I did not experience some of those attacks? What if I had a chance to live a life with fewer days stuck in the wake of an attack?

That is right around the time my doctor introduced me to TAKHZYRO. My doctor and I were drawn to the efficacy data and the idea of me possibly experiencing fewer and less severe future attacks.

We discussed how TAKHZYRO works to control the flow of bradykinin in the body, which is the substance that causes our painful attacks, and I was instantly drawn to it. And as you can see, my family is growing at this point. I did want to be more available because now we have new little ones that we have got to run after and take care of. I want to be active with them too.

I like the idea of taking TAKHZYRO once every two weeks because I could see that as a good fit for my lifestyle. We also make sure to discuss the potential risks and I think Dr. Soteres has mentioned all these allergic reactions as well as some more common ones like injection site reactions, upper respiratory infections, and headaches. Those are all-important factors to consider when you are deciding how to treat your HAE.

After discussing all of those important points, my doctor and I decided it was time to move forward with TAKHZYRO and take a preventive approach to managing my HAE.

For all that went into my decision to start TAKHZYRO, my first preventative treatment, I am happy to be here and tell you it has been a good option for me.

I have consistently gone months between attacks, and I even went a year between early 2019 and early 2020 without a single attack. It is surreal to say that aloud. I never thought that that would be possible. These results have given both my doctor and I confidence in how we are managing and possibly preventing future attacks. Of course, these are my experiences and not everyone will be the same, so please make sure you work with your doctor to see if it would be a good option for you.

Accepting my condition and accepting that I needed to take treating my HAE seriously was a life changing shift for me.

It is something that would not have been possible if I had not taken the leap to become more involved with this community. It is like I had lived alone in a dark room, afraid of what was outside the walls that I had built up around myself, only to realize the support I needed was just on the other side.

Fear is such a powerful thing; it can stop us from becoming the people we dream of being. I do not want to look back on my life and see what has happened to me or my daughters. In the moment you are most afraid, remember, you are in charge of how you manage your HAE and how you engage with the HAE community.

You have the power to decide what is best for you. There will still be moments when you feel overwhelmed by this disease, but there's so much hope and progress in the HAE community.

I want the same for all of you - live life on your own terms. Educate yourself. Reach out for support from others, and never lose hope.

Thanks again for being here.

Takeda Host Kristi Christensen: We roll right into another poll question.

On behalf of Takeda and the marketing team, I get the opportunity to talk about additional resources that we provide, and this is perfect because Dr. Soteres led us right up for this. The first resource is a doctor discussion guide. If you would like to see your healthcare provider prepared, you can use that discussion guide to guide those conversations and ask questions like, how many attacks have you had in the last six months and ask you to rate the severity of those attacks just for an example. The next thing is the YouTube channel where you can hear from other patients with HAE about their experiences. One of those patients actually is Pam. You can see Pam on the YouTube channel talking about her experience.

Next is the toolkit. A lot of people like to have something to get them started. So, this includes an attack tracker, a medical ID card and more.

Then there is a text reminder program. If any of you are like me, I rely on text reminders daily for almost everything in my life. The text reminder program will remind you when those two weeks are coming up and it is time to take your next dose of TAKHZYRO.

Here we go. This is the poll question.

It looks very similar to the first poll question.

We will see if anything has changed since Dr. Soteres presented all our clinical trial information and we talked about resources.

We started with an 88% long term attack reduction. This has shifted just a little bit, and safety has become maybe even a little bit more important.

Thank you for that.

The next thing is our OnePath product support. We are very fortunate to have a few ways that OnePath can help along your journey. The first one is a dedicated patient support manager. Your PSM (Patient Support Manager) is a single point of contact that you will have through your entire journey to help you with any TAKHZYRO support needs that you may have.

Next is financial assistance options. When it comes to finding out about things like copay assistance for those who are eligible, or any assistance that you need navigating any kind of insurance coverage, OnePath is there to help you with those things. Injection training: when you get started on TAKHZYRO, you may need someone to teach you how to do that.

OnePath will set up in home training from a nurse that is trained just to teach you how to give your injection or to help you teach a caregiver how to do that for you. Then the last thing is resources and education. Connecting you and your family members with educational resources, including the OnePath mobile app.

You can see that there is a QR code here if you would like to scan it, you can learn more about the things that are offered through one path through that link.

Then, what to expect from OnePath? That toolkit that we discussed on the resources slide will be shipped to you from OnePath and your PSM and your one path team will facilitate a benefits investigation. They will make a call to your insurance company to find out what your coverage will look like for TAKHZYRO and then figure out from there what kind of financial and coverage options you have.

Then TAKHZYRO will be delivered by a specialty pharmacy directly to you and not to your doctor, but to your home.